Expres2ion Biotech

Financial Calendar

• 24/02/22

  Year-end report, 2021

• 19/05/22

  Interim report, Q1 2022

• 18/08/22

  Half-year report, 2022

• 17/11/22

  Interim report, Q3 2022

• 09/02/23

  Year-end report, 2022

Latest press releases

Positive topline results reported for the Phase II COVID-19 clinical trial with the ABNCoV2 vaccine

05-12-2021 Regulatory pressrelease

Hørsholm, Denmark, December 5, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the ABNCoV2 vaccine demonstrated a strong boosting effect in the clinical Phase II trial conducted by Bavarian Nordic. The existing levels of SARS-CoV-2 neutralizing antibodies increased by 2-40-fold, depending on the initial levels of antibodies, with no serious…

Read more

ExpreS2ion will participate in key investor events in December 2021

29-11-2021 Non-regulatory pressrelease

Hørsholm, Denmark, November 29, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in December. These include events hosted by Aktiespararna and HC Andersen Capital in collaboration with Nordea Markets.

Read more

View all